To report on the FDA's approval of Immgolis and Immgolis Intri as interchangeable biosimilars to Simponi and Simponi Aria for rheumatoid arthritis and ulcerative colitis.
Key Findings:
Immgolis and Immgolis Intri are the first interchangeable biosimilars for golimumab.
Pharmacokinetic analyses showed similar exposure and immunogenicity profiles.
Interchangeable biosimilars allow for pharmacy-level substitution under FDA standards.
Interpretation:
The approval of these biosimilars is expected to provide lower-cost treatment options while maintaining comparable clinical outcomes to the reference biologics.
Limitations:
The safety profile includes risks of serious infections and malignancies.
Common adverse events reported are similar to those of the reference products.
Conclusion:
The introduction of Immgolis and Immgolis Intri represents a significant advancement in treatment options for rheumatoid arthritis and ulcerative colitis, potentially improving access to care.
A systematic review of more than 2.3 million patients found that women and men had different patterns of postoperative complications and recovery, with age and implant strategy modifying observed differences.
